Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit

American Journal of Health-System Pharmacy

Volumn 63, Issue 19, 2006, Pages 1876-1881

  Kane Gill, Sandra ^a   Rea, Rhonda S ^b,c   Verrico, Margaret M ^b,d   Weber, Robert J ^b,e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Universigy of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UPMC

^e UPMC ^*

Author keywords

Costs; Drug use; Drugs, adverse reactions; Errors, medication; Hospitals; Pharmacists, hospital

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; FAMOTIDINE; FENTANYL; HALOPERIDOL; HEPARIN; LEVOFLOXACIN; MORPHINE; PHENYTOIN; PIPERACILLIN; PROPOFOL; TACROLIMUS; VANCOMYCIN; WARFARIN;

ADULT; AGED; ARTICLE; CRITICAL ILLNESS; DATA BASE; DRUG COST; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG UTILIZATION; FEMALE; HOSPITAL PHARMACY; HUMAN; INFORMATION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT;

EID: 33749162955     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060045     Document Type: Article

References (36)

1. Leape LL, Brennan TA, Laird N et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
2. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-6.
3. Cullen DJ, Sweitzer BJ, Bates DW et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997; 25:1289-97.
4. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA. 1995; 274:29-34.
5. Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. J Gen Intern Med. 1993; 8:278-83.
6. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11.
7. Food and Drug Administration. FDA and Lincoln Technologies, Inc. to collaborate on developing tools for safety data mining. www.fda.gov/bbs/topics/ NEWS/2003/NEW00899.html (accessed 2006 Jan 31).
8. Kane-Gill SL, Dasta JF, Schneider PJ et al. Monitoring abnormal laboratory values as antecedents to drug-induced injury. J Trauma. 2005; 59:1457-62.
9. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
10. [Erratum, JAMA. 2000; 283:1293.]
11. Kucukarslan SN, Peters M, Mlynarek M et al. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Int Med. 2003; 163:2014-8.
12. Silverman JB, Stapinski CD, Huber C et al. Computer-based system for preventing adverse drug events. Am J Health-Syst Pharm. 2004; 61:1599-1603.
13. Rudis MI, Brandl KM. Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Clinical Pharmacy Task Force on Critical Care Pharmacy Services. Crit Care Med. 2000; 28:3746-50.
14. Racine E. Justifying high-cost anticoagulant therapy. Am J Health-Syst Pharm. 2002; 59(suppl 6):S18-20.
15. Halley HJ. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health-Syst Pharm. 2000; 57(suppl 3):S17-21.
16. Weber RJ, Kane SL, Oriolo VA et al. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med. 2003; 31(suppl 1):S17-24.
17. Dasta JF, Durtschi AJ, Kane-Gill SL. Pharmacoeconomics in critical care. In: Grenvik A, ed. Textbook of critical care. 5th ed. Philadelphia: Saunders, 2005:1732-9.
18. Constantini O, Papp KK, Como J et al. Attitudes of faculty, housestaff and medical students toward clinical practice guidelines. Acad Med. 1999; 74:1138-43.
19. [Erratum, Acad Med. 1999; 74:1322.]
20. Fischer MA, Lilly CM, Churchill WW et al. An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre. Drug Saf. 2004; 27:1253-61.
21. Senst BL, Achusim LE, Genest RP et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health-Syst Pharm. 2001; 58:1126-32.
22. National Cancer Institute. National Cancer Institute common terminology criteria for adverse events v 3.0. http:// ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 2006 Jan 31).
23. Jones JK. Definition of events associated with drugs: regulatory perspectives. J Rheumatol Suppl. 1988; 17:14-9.
24. Dasta JF. Drug use in a surgical intensive care unit. Drug Intell Clin Pharm. 1986; 20:752-6.
25. Boucher BA, Kuhl DA, Coffey BC et al. Drug use in a trauma intensive-care unit. Am J Hosp Pharm. 1990; 47:805-10.
26. Mann HJ, Wittbrodt ET. Identifying drug usage patterns in the intensive care unit. Pharmacoeconomics. 1993; 4:235-9.
27. Hassan Y, Aziz NA, Awang J et al. An analysis of clinical pharmacist interventions in an intensive care unit. J Clin Pharm Ther. 1992; 17:347-51.
28. Lata PF, Mainhardt M, Johnson CA. Impact of nurse case manager-pharmacist collaboration on adverse-drug-event reporting. Am J Health-Syst Pharm. 2004; 61:483-7.
29. Van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LT. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11:205-10.
30. Van Grootheest K, Olsson S, Couper M et al. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004; 13:457-64.
31. Duwe B, Fuchs BD, Hansen-Flaschen J. Failure mode and effects analysis application to critical care medicine. Crit Care Clin. 2005; 21:21-30.
32. Jha AK, Kuperman GJ, Teich JM et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998; 5:305-14.
33. Dormann H, Muth-Selbach U, Krebs S et al. Incidence and costs of adverse drug reactions during hospitalization: computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000; 22:161-8.
34. Thurmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. 2001; 24:961-8.
35. Kane-Gill SL, Devlin J. Adverse drug event reporting in intensive care units: a survey of current practices. Ann Pharmacother. DOI.1345/aph.1H088; 2006 Jul 18.
36. Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann Pharmacother. 2005; 39:1823-7.